Ursodeoxycholic Acid Orion: Uses, Dosage & Side Effects
A naturally occurring bile acid used to dissolve cholesterol gallstones and treat primary biliary cholangitis (PBC), also used for hepatobiliary disease in cystic fibrosis
Ursodeoxycholic Acid Orion contains ursodeoxycholic acid (UDCA), a naturally occurring bile acid found in small amounts in human bile. It is prescribed for two main conditions: dissolving small, non-calcified cholesterol gallstones in patients for whom surgery is not appropriate, and treating primary biliary cholangitis (PBC, formerly known as primary biliary cirrhosis) to stimulate bile flow and slow disease progression. In children and adolescents aged 6 to 18 years, it is also approved for treating hepatobiliary disease associated with cystic fibrosis. This medication is available as 250 mg hard capsules and requires a prescription. It is also marketed under the brand name Ursogrix.
Quick Facts: Ursodeoxycholic Acid Orion
Key Takeaways
- Ursodeoxycholic acid (UDCA) is a naturally occurring bile acid that reduces cholesterol saturation in bile, enabling the gradual dissolution of small, non-calcified cholesterol gallstones over a treatment period of 6 to 24 months.
- In primary biliary cholangitis (PBC), UDCA is the first-line treatment recommended by all major hepatology guidelines (EASL, AASLD); it stimulates bile flow, protects liver cells from toxic bile acids, and can significantly slow disease progression when started early.
- Do not use this medication if you have acute gallbladder or bile duct inflammation, bile duct obstruction, frequent biliary colic, calcified gallstones, or impaired gallbladder contractility.
- Women taking UDCA for gallstone dissolution must use non-hormonal contraception, as hormonal contraceptives can promote gallstone formation; the medication should generally be avoided during pregnancy.
- The most common side effect is diarrhea; if persistent, the dose may need adjustment. Liver function tests should be monitored during the first three months of treatment.
What Is Ursodeoxycholic Acid Orion and What Is It Used For?
Ursodeoxycholic Acid Orion contains the active substance ursodeoxycholic acid (UDCA), which is a naturally occurring bile acid found in small quantities in human bile. Under normal physiological conditions, UDCA constitutes only about 1–3% of the total bile acid pool. However, when administered therapeutically, it gradually becomes the predominant bile acid, comprising up to 40–60% of the total bile acid pool. This shift in bile acid composition is the foundation of its therapeutic effects.
Bile acids are synthesized in the liver from cholesterol and play an essential role in digestion, particularly in the emulsification and absorption of dietary fats and fat-soluble vitamins (A, D, E, and K). They are secreted into the small intestine via the bile ducts and gallbladder, where they perform their digestive functions, and are then largely reabsorbed in the terminal ileum and returned to the liver via the enterohepatic circulation. This recycling pathway is remarkably efficient, with approximately 95% of bile acids being reclaimed with each cycle.
UDCA is distinguished from other bile acids by its hydrophilic (water-soluble) nature. Most endogenous bile acids, such as chenodeoxycholic acid (CDCA) and deoxycholic acid (DCA), are hydrophobic and can be toxic to cell membranes at high concentrations. UDCA, by contrast, lacks this cytotoxicity and actually protects hepatocytes (liver cells) and cholangiocytes (bile duct cells) from the damaging effects of more hydrophobic bile acids. This cytoprotective property is central to its therapeutic benefit in liver diseases.
Gallstone Dissolution
The primary use of UDCA in this formulation is the dissolution of small cholesterol gallstones. Cholesterol gallstones form when bile becomes supersaturated with cholesterol — that is, when the cholesterol concentration exceeds the capacity of bile acids and phospholipids to keep it in solution. UDCA addresses this by reducing hepatic cholesterol secretion into bile and inhibiting intestinal cholesterol absorption, thereby decreasing cholesterol saturation. Over time, this creates conditions that favor the gradual dissolution of existing cholesterol stones.
This treatment approach is most effective for small (typically less than 15–20 mm in diameter), radiolucent (non-calcified) cholesterol gallstones in patients with a functioning gallbladder. Calcified stones, pigment stones, and very large stones do not respond to bile acid dissolution therapy. The European Association for the Study of the Liver (EASL) guidelines recommend UDCA dissolution therapy as an alternative to surgery in selected patients, particularly those who are poor surgical candidates or who decline cholecystectomy.
Primary Biliary Cholangitis (PBC)
The second major indication for Ursodeoxycholic Acid Orion is primary biliary cholangitis (PBC), a chronic autoimmune liver disease characterized by progressive destruction of the small intrahepatic bile ducts. This leads to cholestasis (impaired bile flow), accumulation of toxic bile acids within the liver, and if untreated, progressive fibrosis that can ultimately lead to cirrhosis and liver failure.
UDCA is universally recommended as the first-line pharmacological treatment for PBC by all major hepatology societies, including EASL, the American Association for the Study of Liver Diseases (AASLD), and the British Society of Gastroenterology (BSG). When administered at the recommended dosage of 13–15 mg/kg/day, UDCA has been shown to improve biochemical markers of liver disease (particularly alkaline phosphatase and bilirubin), slow histological progression, delay the development of esophageal varices, and improve transplant-free survival. The landmark meta-analyses and long-term follow-up studies have consistently demonstrated that early initiation of UDCA therapy, particularly in patients at earlier disease stages, is associated with the best outcomes.
Cystic Fibrosis-Associated Liver Disease
In children and adolescents aged 6 to 18 years, Ursodeoxycholic Acid Orion is approved for the treatment of hepatobiliary disease associated with cystic fibrosis (CF). Cystic fibrosis-related liver disease (CFLD) affects approximately 25–40% of patients with CF and is the third leading cause of death in this population, after pulmonary disease and transplant-related complications. The thick, dehydrated bile secretions characteristic of CF can obstruct small bile ducts, leading to focal biliary cirrhosis and, in some cases, multilobular cirrhosis.
UDCA is thought to benefit CF patients by improving bile flow, reducing the viscosity of bile secretions, and protecting cholangiocytes from bile acid-mediated injury. While the evidence base for UDCA in CF liver disease is less robust than for PBC, it remains a widely used and guideline-recommended treatment in clinical practice, supported by observational studies showing improvements in liver biochemistry and, in some studies, histological improvement.
Ursodeoxycholic acid gets its name from the Latin ursus (bear), as it was first identified in bear bile, which has been used in traditional Chinese medicine for centuries. Modern pharmaceutical UDCA is produced synthetically and is chemically identical to the naturally occurring substance. It is one of the most well-established hepatoprotective agents in clinical medicine, with over 40 years of evidence supporting its use.
What Should You Know Before Taking Ursodeoxycholic Acid Orion?
Contraindications
There are several specific situations in which Ursodeoxycholic Acid Orion must not be used. Understanding these absolute contraindications is essential before starting treatment, as use of UDCA in these circumstances could worsen the underlying condition or be ineffective.
- Hypersensitivity: Do not take this medication if you are allergic to ursodeoxycholic acid or to any of the other ingredients listed in the composition section (maize starch, colloidal hydrated silica, magnesium stearate, titanium dioxide E171, or gelatin).
- Acute cholecystitis or cholangitis: Active inflammation of the gallbladder or bile ducts is an absolute contraindication. UDCA stimulates bile flow, which could worsen pain and potentially precipitate complications such as gallbladder perforation or ascending cholangitis in the setting of acute inflammation.
- Common bile duct or cystic duct obstruction: If the bile ducts are blocked, increasing bile flow with UDCA could lead to dangerous pressure buildup proximal to the obstruction, potentially causing bile duct rupture or worsening obstructive jaundice.
- Frequent biliary colic: Patients experiencing frequent episodes of cramping upper abdominal pain (biliary colic) are not suitable candidates for medical dissolution therapy. Recurrent colic suggests either a large stone burden or stones positioned in ways that predispose to duct obstruction, and such patients generally require surgical intervention.
- Calcified gallstones: Only pure or predominantly cholesterol gallstones can be dissolved by UDCA. Calcified stones, which appear radio-opaque on imaging, have a calcium carbonate or calcium bilirubinate shell that is resistant to bile acid dissolution. Attempting to dissolve calcified stones with UDCA is futile and delays appropriate treatment.
- Impaired gallbladder contractility: For gallstone dissolution to succeed, the gallbladder must contract adequately to expel bile enriched with UDCA. A non-functioning or poorly contracting gallbladder (as may be demonstrated by oral cholecystography or hepatobiliary scintigraphy) means the medication cannot reach the stones effectively.
- Biliary atresia in children: In children with biliary atresia (absence or closure of the bile ducts), UDCA is contraindicated because there is no functional bile drainage pathway. These children require surgical intervention (Kasai portoenterostomy) rather than medical therapy.
Warnings and Precautions
Several important precautions should be observed during treatment with Ursodeoxycholic Acid Orion. Discuss these with your doctor before starting therapy and report any concerning symptoms promptly.
Liver function monitoring: During the first three months of treatment, your doctor should perform regular blood tests to monitor liver function. These tests help confirm that the treatment is working as expected and allow early detection of any adverse hepatic effects. The key parameters monitored include alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), and bilirubin. In PBC, an adequate biochemical response to UDCA (defined by EASL criteria) is an important predictor of long-term outcomes.
Initial symptom worsening in PBC: In rare cases, patients being treated for primary biliary cholangitis may experience a temporary worsening of symptoms, particularly pruritus (itching), at the start of treatment. If this occurs, your doctor may reduce the daily dose and then gradually increase it each week until the recommended dose is reached. This paradoxical worsening is thought to result from the initial shift in bile acid pool composition and usually resolves as UDCA becomes the dominant bile acid.
Diarrhea: If you develop diarrhea during treatment, it is important to inform your doctor. Diarrhea is the most common side effect of UDCA and is dose-related. Your doctor may need to reduce the dose or, in cases of persistent severe diarrhea, consider discontinuing treatment. Dehydration from prolonged diarrhea can be a concern, particularly in elderly patients or those with other medical conditions.
Pregnancy and Breastfeeding
Ursodeoxycholic Acid Orion should not be used during pregnancy unless your doctor considers it absolutely necessary. Animal reproductive studies have shown some evidence of fetotoxicity at high doses, and although human data are limited, the potential risk to the developing fetus means that the drug should only be used when the benefit clearly outweighs the risk. Before starting treatment, a pregnancy test should be performed to rule out pregnancy.
Women of childbearing age should use reliable contraception throughout treatment. For women being treated for gallstone dissolution, non-hormonal contraceptive methods are specifically required, because estrogen-containing hormonal contraceptives (such as combined oral contraceptive pills) can increase biliary cholesterol secretion and thereby promote the formation of new gallstones, directly counteracting the therapeutic goal of UDCA treatment. Low-dose estrogen contraceptive pills or non-hormonal methods (such as copper intrauterine devices, barrier methods, or progestogen-only contraceptives) are recommended alternatives.
It is currently unknown whether ursodeoxycholic acid is excreted in human breast milk. Limited animal data suggest minimal transfer into milk, but in the absence of definitive human data, women should consult their doctor before breastfeeding while taking this medication. The decision to breastfeed during UDCA therapy should weigh the benefit of breastfeeding for the infant against the potential risk of drug exposure.
Driving and Operating Machinery
There is no known effect of ursodeoxycholic acid on the ability to drive or operate machinery. No studies have demonstrated any impairment of cognitive function, reaction time, or psychomotor performance with UDCA use. Patients can generally continue driving and performing activities requiring alertness without restriction while taking this medication.
How Does Ursodeoxycholic Acid Orion Interact with Other Drugs?
Drug interactions with ursodeoxycholic acid can be broadly categorized into those that affect its absorption, those that affect its therapeutic efficacy, and those where UDCA alters the pharmacokinetics of other drugs. Understanding these interactions is important for optimal treatment outcomes, and patients should always inform their doctor about all medications they are taking, including over-the-counter products and herbal supplements.
Major Interactions
The following interactions are considered clinically significant and require either avoidance of the combination, dose adjustment, or careful timing of administration.
| Interacting Drug | Effect | Management |
|---|---|---|
| Cholestyramine / Colestipol | Bile acid sequestrants bind UDCA in the intestine, markedly reducing its absorption and therapeutic effect | Take UDCA at least 2 hours before or after bile acid sequestrants |
| Aluminum hydroxide antacids | Aluminum-containing antacids can bind UDCA and reduce its intestinal absorption | Take UDCA at least 2 hours before or after aluminum-containing antacids |
| Ciclosporin (cyclosporine) | UDCA may increase intestinal absorption of ciclosporin, leading to elevated blood levels and increased risk of nephrotoxicity | Monitor ciclosporin blood levels closely; dose adjustment of ciclosporin may be required |
| Estrogen-containing medications | Estrogens increase biliary cholesterol secretion, potentially promoting gallstone formation and counteracting dissolution therapy | Use non-hormonal or low-dose estrogen contraception during gallstone treatment |
| Clofibrate | Increases biliary cholesterol secretion, directly counteracting the mechanism of UDCA gallstone dissolution | Avoid concomitant use during gallstone dissolution therapy; discuss alternative lipid-lowering agents |
Minor Interactions
The following interactions are of lesser clinical significance but should still be considered and discussed with your healthcare provider.
| Interacting Drug | Effect | Management |
|---|---|---|
| Ciprofloxacin | UDCA may alter the absorption of ciprofloxacin, potentially affecting antibiotic efficacy | Monitor for adequate antimicrobial response; consider separating doses |
| Nitrendipine | UDCA may increase the bioavailability of nitrendipine, potentially enhancing its blood pressure-lowering effect | Monitor blood pressure; dose adjustment may be needed |
| Dapsone | UDCA may affect the absorption of dapsone | Monitor therapeutic response and adjust dose if necessary |
| Rosuvastatin | Concomitant use may affect the plasma levels of rosuvastatin | Monitor lipid levels and consider dose adjustment of the statin |
For medications that interact with UDCA through binding in the intestine (cholestyramine, colestipol, aluminum-containing antacids), the most practical strategy is to separate the doses by at least 2 hours. Take UDCA either 2 hours before or 2 hours after these medications to ensure adequate absorption. If you are unsure about when to take your medications, ask your doctor or pharmacist for a personalized dosing schedule.
What Is the Correct Dosage of Ursodeoxycholic Acid Orion?
Always take this medicine exactly as your doctor or pharmacist has told you. Do not change the dose without consulting your healthcare provider. The hard capsules should be swallowed whole with liquid — do not open, crush, or chew them. The following dosage information provides general guidance; your doctor will determine the most appropriate dose for your individual situation.
Adults
Gallstone Dissolution
Dose: 10–12 mg/kg body weight per day, divided into 2 doses (morning and evening).
Duration: Treatment generally takes 6 to 24 months for complete gallstone dissolution. Your doctor will assess progress after 6 to 10 months using imaging studies (typically ultrasound). If there has been no reduction in stone size after 12 months, the treatment should be discontinued.
Example: A 70 kg patient would take approximately 750 mg per day (3 capsules), divided as 1 capsule in the morning and 2 capsules in the evening, or as directed by their physician.
Primary Biliary Cholangitis (PBC)
Dose: 12–16 mg/kg body weight per day.
Initial period (first 3 months): The daily dose should be divided into multiple doses taken throughout the day (typically morning, midday, and evening). This gradual introduction helps minimize gastrointestinal side effects and allows monitoring of the initial response.
After liver values improve: The entire daily dose may be taken once daily, preferably in the evening, for greater convenience and improved compliance.
Duration: Treatment of PBC with UDCA is generally continued indefinitely (lifelong), as discontinuation can lead to disease rebound. International guidelines (EASL 2017, AASLD 2019) recommend lifelong therapy for all PBC patients.
Children (6–18 years)
Cystic Fibrosis-Associated Liver Disease
Dose: 20 mg/kg body weight per day, divided into 2 to 3 doses.
Dose escalation: If necessary, the dose may be increased up to 30 mg/kg/day, based on clinical response and tolerability.
Note: This medication is not intended for children under 6 years of age for this indication. Pediatric dosing should always be determined and supervised by a specialist physician experienced in the management of cystic fibrosis.
Elderly Patients
No specific dose adjustment is generally required for elderly patients. However, elderly patients may be more susceptible to diarrhea (the most common side effect) and its consequences, particularly dehydration. Physicians should exercise caution and consider starting at the lower end of the dosing range, with gradual dose increases as tolerated. Renal function should be considered in elderly patients, although UDCA is primarily eliminated via the fecal route rather than renal excretion.
Missed Dose
If you forget to take a dose of Ursodeoxycholic Acid Orion, simply skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for the missed one. Missing a single dose is unlikely to have any significant impact on treatment efficacy, as UDCA therapy works through the gradual accumulation and enrichment of the bile acid pool over weeks to months. However, consistent adherence to the prescribed regimen is important for optimal results, particularly in gallstone dissolution therapy where the cumulative effect over time is critical.
Overdose
If you take more Ursodeoxycholic Acid Orion than prescribed, or if a child accidentally ingests the medication, contact your doctor, nearest hospital emergency department, or poison control center immediately for assessment and advice. The primary symptom expected from overdose is diarrhea, as UDCA has a relatively wide therapeutic margin. Severe toxicity is uncommon even at supra-therapeutic doses, but medical assessment is still recommended to ensure appropriate monitoring. There is no specific antidote for UDCA overdose; treatment is supportive and focused on managing symptoms, particularly fluid and electrolyte replacement if significant diarrhea occurs.
Always speak to your doctor before stopping Ursodeoxycholic Acid Orion. In patients being treated for PBC, abrupt discontinuation can lead to a rapid worsening of liver biochemistry (rebound cholestasis) and potentially accelerate disease progression. Any decision to stop or change the treatment should be made in consultation with your doctor.
What Are the Side Effects of Ursodeoxycholic Acid Orion?
Like all medicines, ursodeoxycholic acid can cause side effects, although not everybody gets them. Overall, UDCA is considered one of the better-tolerated medications in gastroenterology and hepatology, with a favorable safety profile that has been well-established over decades of clinical use. Most side effects are mild and dose-related, meaning they can often be managed by adjusting the dose.
The following side effects have been reported with ursodeoxycholic acid, classified by frequency according to standard medical convention:
Common
May affect up to 1 in 10 patients
- Diarrhea — The most frequently reported side effect. Usually mild to moderate and dose-related. Often improves with dose reduction or can be managed by taking the capsules with food. Persistent or severe diarrhea should be reported to your doctor.
- Pale (light-colored) stools — A direct consequence of the altered bile acid composition. The change in stool color is harmless and does not indicate a problem, though it can be mistaken for a sign of bile duct obstruction. If you have concerns, consult your doctor.
Very Rare
May affect up to 1 in 10,000 patients
- Severe right upper abdominal pain — Reported in some patients being treated for primary biliary cholangitis (PBC). This may indicate a complication of the underlying liver disease rather than a direct drug effect. Report this symptom to your doctor immediately.
- Deterioration of liver function — In rare cases during PBC treatment, liver function tests may worsen. This is typically reversible upon discontinuation of the medication. Regular liver function monitoring during the first three months of treatment helps detect this complication early.
- Calcification of gallstones — Paradoxically, in rare instances, gallstones may develop a calcium shell during UDCA treatment, making them resistant to further dissolution. If this occurs, medical dissolution therapy should be discontinued.
- Urticaria (hives) — An allergic skin reaction characterized by raised, itchy welts. If you develop urticaria, contact your doctor, as this may indicate an allergic reaction requiring treatment modification.
If you experience any side effects, whether or not they are listed above, talk to your doctor, pharmacist, or nurse. You can also report side effects directly to your national regulatory authority. By reporting side effects, you help provide more information on the safety of this medicine.
UDCA has one of the most favorable safety profiles among hepatoprotective medications. Large clinical trials and decades of post-marketing surveillance confirm that serious adverse events are rare. The majority of patients taking UDCA for PBC tolerate it well for years or even decades of continuous use. The main practical consideration is monitoring for diarrhea, which is typically manageable with dose adjustment.
How Should You Store Ursodeoxycholic Acid Orion?
Proper storage of medication ensures that it remains effective and safe throughout its shelf life. Ursodeoxycholic Acid Orion capsules should be stored under the following conditions:
- Temperature: Store at or below 30°C (86°F). Do not refrigerate or freeze the capsules. Avoid storing in locations subject to high temperatures, such as inside a car during summer or near radiators or heating vents.
- Moisture protection: The capsules are sensitive to moisture. Always keep them in the original blister packaging until you are ready to take a dose. Do not transfer capsules to other containers unless they provide equivalent moisture protection.
- Light exposure: While not specifically noted as light-sensitive, it is good practice to store the medication in its original packaging, which provides some protection from light.
- Child safety: Keep this medicine out of sight and reach of children. The gelatin capsules may be attractive to young children, and accidental ingestion could cause diarrhea.
- Expiry date: Do not use this medication after the expiry date stated on the packaging after “EXP.” The expiry date refers to the last day of the stated month. After expiry, the chemical stability of the active ingredient may no longer be guaranteed.
- Disposal: Do not dispose of medications via wastewater or household waste. Return unused or expired medications to a pharmacy for environmentally safe disposal. Active pharmaceutical ingredients in wastewater can harm aquatic ecosystems.
What Does Ursodeoxycholic Acid Orion Contain?
Understanding the full composition of your medication is important, particularly if you have known allergies or intolerances to specific excipients. The following provides a detailed breakdown of the contents of Ursodeoxycholic Acid Orion 250 mg hard capsules.
Active Ingredient
Each hard capsule contains 250 mg of ursodeoxycholic acid (also known as ursodiol in some markets). Ursodeoxycholic acid is a white or almost white crystalline powder that is practically insoluble in water but soluble in ethanol and glacial acetic acid. Its molecular formula is C24H40O4 and its molecular weight is 392.57 g/mol.
Inactive Ingredients (Excipients)
The inactive ingredients serve various pharmaceutical functions such as filling, binding, lubricating, and forming the capsule shell:
- Capsule contents: Maize starch (filler/binder), colloidal hydrated silica (anti-caking agent), magnesium stearate (lubricant)
- Capsule shell: Titanium dioxide (E171, opacifier/colorant), gelatin (capsule forming agent)
Appearance and Packaging
Ursodeoxycholic Acid Orion capsules are white, hard gelatin capsules approximately 21.7 mm × 7.64 mm in size, containing a white or almost white powder. The capsules are packed in PVC/aluminum blisters. Available pack sizes are 25, 50, 75, and 100 capsules. Not all pack sizes may be marketed in every country.
Manufacturer
Ursodeoxycholic Acid Orion is manufactured by Orion Corporation, based in Espoo, Finland, with additional manufacturing sites in Salo, Finland, and by Grindeks in Riga, Latvia. The marketing authorization holder is Orion Corporation, Orionintie 1, FI-02200 Espoo, Finland.
Frequently Asked Questions About Ursodeoxycholic Acid Orion
Ursodeoxycholic acid and ursodiol are two names for the same active substance. “Ursodeoxycholic acid” (abbreviated UDCA) is the International Nonproprietary Name (INN) used in Europe and most of the world, while “ursodiol” is the United States Adopted Name (USAN) used primarily in the United States. Regardless of the name used, the chemical compound and its therapeutic effects are identical. Different brand names are available in different countries (e.g., Ursodeoxycholic acid Orion, Ursogrix, Actigall, Urso, Ursofalk), but they all contain the same active ingredient.
The duration of treatment depends entirely on the condition being treated. For gallstone dissolution, treatment typically lasts 6 to 24 months and is discontinued once the stones have dissolved (confirmed by imaging) or if no progress is seen after 12 months. For primary biliary cholangitis (PBC), treatment is generally lifelong, as stopping the medication can lead to worsening of the disease. For cystic fibrosis-associated liver disease in children, treatment is usually continued long-term under specialist supervision. Never stop taking the medication without first consulting your doctor.
No. Ursodeoxycholic acid can only dissolve cholesterol gallstones that are small (generally less than 15–20 mm in diameter), non-calcified (radiolucent on X-ray), and located in a functioning gallbladder. Calcified stones (which appear white on X-ray), pigment stones (made of bilirubin rather than cholesterol), very large stones, and stones in patients with a non-functioning gallbladder will not respond to UDCA treatment. Your doctor will assess your gallstones using imaging studies before starting therapy to determine whether medical dissolution is appropriate for your specific situation.
Yes, ursodeoxycholic acid has an excellent long-term safety profile. Many patients with PBC take this medication continuously for decades, and long-term studies have consistently confirmed its safety. UDCA is a naturally occurring substance in human bile, which contributes to its favorable tolerability. Long-term monitoring of liver function is still recommended, but serious adverse effects with prolonged use are rare. The benefit of continued UDCA therapy in PBC patients — slowing disease progression and improving survival — clearly outweighs the minimal risks of long-term use.
There is no specific interaction between ursodeoxycholic acid and alcohol. However, if you are taking UDCA for a liver condition such as primary biliary cholangitis, your doctor will likely advise you to limit or avoid alcohol consumption, as alcohol can cause additional liver damage and may worsen the underlying disease. For patients being treated for gallstone dissolution, moderate alcohol consumption is generally acceptable, but excessive alcohol intake should be avoided as it can affect liver function. Always discuss your alcohol consumption with your doctor, particularly if you have any liver condition.
There is a possibility of gallstone recurrence after successful dissolution therapy with UDCA. Studies suggest that approximately 30–50% of patients may develop new gallstones within 5 years of stopping treatment. The risk of recurrence is higher in patients with multiple risk factors for gallstone formation, such as obesity, rapid weight loss, or a diet high in cholesterol. Some physicians recommend a period of low-dose maintenance therapy after successful dissolution to reduce the recurrence risk. Lifestyle modifications, including maintaining a healthy weight, eating a balanced diet, and regular physical activity, may also help prevent recurrence.
References
- European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. Journal of Hepatology. 2017;67(1):145–172.
- Lindor KD, Bowlus CL, Boyer J, et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (AASLD). Hepatology. 2019;69(1):394–419.
- European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. Journal of Hepatology. 2016;65(1):146–181.
- British National Formulary (BNF). Ursodeoxycholic acid monograph. National Institute for Health and Care Excellence (NICE). 2025.
- Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clinics and Research in Hepatology and Gastroenterology. 2012;36(Suppl 1):S3–S12.
- Colombo C, Battezzati PM, Podda M, et al. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. Hepatology. 1996;23(6):1484–1490.
- Corpechot C, Chazouillères O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. Journal of Hepatology. 2011;55(6):1361–1367.
- European Medicines Agency (EMA). Summary of Product Characteristics: Ursodeoxycholic acid-containing medicinal products. 2024.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: WHO; 2023.
Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in gastroenterology, hepatology, and clinical pharmacology. Our editorial process follows the GRADE evidence framework, and all medical claims are supported by peer-reviewed research and international clinical guidelines.
All content reviewed by board-certified physicians following EASL, AASLD, and WHO guidelines. Evidence Level 1A where applicable.
Independent medical content with no pharmaceutical industry funding or influence. Updated regularly to reflect current evidence and guideline changes.
Last reviewed: | Published: | Meet Our Medical Team | Editorial Standards